Related Experiment Videos
Protective effect of Prostane in experimental prostatic hyperplasia in rats
S K Mitra1, R Sundaram, A R Mohan
1R&D Centre, The Himalaya Drug Co, Makali, Bangalore, India. skmitra@bgl.vsnl.net.in
Asian Journal of Andrology
|February 28, 2001
Summary
Prostane, a polyherbal formulation, effectively inhibited 5alpha-reductase and alpha-adrenergic activity, reducing experimental prostatic hypertrophy in rats. Further trials for benign prostatic hypertrophy are suggested.
Area of Science:
- Pharmacology
- Natural Product Research
Background:
- Benign prostatic hypertrophy (BPH) is a common condition in aging men.
- Current treatments for BPH have limitations and side effects.
Purpose of the Study:
- To evaluate the efficacy of Prostane, a polyherbal formulation, in treating experimental prostatic hyperplasia.
- To assess Prostane's effects on 5alpha-reductase inhibition and alpha-adrenergic activity.
Main Methods:
- 5alpha-reductase inhibition was assessed using rat prostate homogenate.
- Alpha-adrenergic antagonistic activity was evaluated using isolated rat vas deferens.
- Experimental prostatic hyperplasia was induced in rats via testosterone administration.
Main Results:
- Prostane demonstrated dose-dependent inhibition of 5alpha-reductase activity.
- Prostane exhibited significant alpha-adrenergic antagonistic activity.
- Prostane treatment reduced prostatic weight, epithelial height, and stromal proliferation in a dose-dependent manner.
Conclusions:
- Prostane is effective in managing experimental prostatic hypertrophy in rats.
- Prostane shows potential for treating benign prostatic hypertrophy in humans.
- Further toxicological evaluations are recommended before clinical trials.